In our study, we could show that also NKG2A+NKG2C+ NK cells efficiently control the proliferation of EBV-infected tumor cells, when they were treated with NKG2A-blocking monoclonal antibodies (Monalizumab). Here, KLRC2 is linked to neoplasm.